Parkway Medical Center LLC | Birmingham, AL

Research site

(Unclaimed)

Location

1160 Huffman Road, Birmingham, Alabama, United States of America

Site insights

Top conditions

Top treatments

Buprenorphine

AC2993

Glucose

Brenipatide

Metformin

TQJ230

CAM2038

Ezetimibe

Donanemab

Alcohol

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 34 total trials

A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD). Approxi...

Active, not recruiting

Alzheimer Disease

Drug: Donanemab

Drug: Placebo

A Study of Brenipatide in Participants With Alcohol Use Disorder (RENEW-ALC-2)

The purpose of this study is to see if brenipatide when compared to a placebo works and is safe for participants with Alcohol Use Disorder (AUD) and...

Begins enrollment this month

Alcohol Use Disorder

Drug: Placebo

Drug: LY3537031

A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder (RENEW-ALC-1)

The purpose of this study is to see if brenipatide when compared to a placebo works and is safe for participants with moderate-to-severe Alcohol Use...

Begins enrollment this month

Alcohol Use Disorder

Drug: LY3537031

Drug: Placebo

A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)

The purpose of this study is to measure the difference in time to developing or worsening memory, thinking, or functional problems due to Alzheimer's...

Active, not recruiting

Alzheimer's Disease

Drug: Placebo

Drug: Remternetug

Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVD

Study CTQJ230A12303 is a randomized, double-blind placebo-controlled, Phase IIIb study to evaluate the efficacy, safety and tolerability of pelacarse...

Active, not recruiting

Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease

Drug: TQJ230

Drug: Placebo

Pelacarsen Roll-over Extension Program

This non-randomized, rollover extension study will provide post-trial access to pelacarsen (TQJ230) to participants who have successfully completed e...

Enrolling

Atherosclerotic Cardiovascular Disease

Drug: Pelacarsen (TQJ230)